In recent years, immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed death (PD)-1, and PD-ligand 1 (PD-L1) have demonstrated durable responses in subsets of patients with metastatic disease (6). This evidence concerns the gene CTLA4 and metastatic neoplasm.